Decisions taken by the EMTC are final unless there is new evidence which was not previously available or considered. In such cases, the request can be re-submitted for re-consideration by the consultant through the EMT unit.

No. Approvals for non-formulary items are procured on a named-patient basis. This means that stocks for each approved patient is bought separately as per dose and quantity specified on the EMT form.  Hence, before a new patient is started on treatment adequate stocks needs to be ensured so that treatment of previously approved patients is not compromised. Once stock availability is confirmed through CPSU, POYC are notified to issue out-patient entitlement documents.

Renewals of exceptionally approved medicines should be made at least 2 months in advance of their expiry in order to allow adequate time for processing and for additional stock to be purchased.  Any increase in dose requires DPA approval before being implemented

The EMTC generally convenes every 4 weeks in order to discuss submitted EMT and make the necessary approvals or rejections. In some cases, further information is requested from the consultant which would then need to be resubmitted to the EMTC.

Urgent requests, which are defined as an EMT request which needs to be assessed before the next scheduled EMTC meeting, are generally submitted to the EMTC within the first working day following submission of application to DPA.

Applications for new treatments, any renewals or change in dose can only be processed if submitted electronically via email address: [email protected].  No hard copies will be accepted.

EMT applications need to be submitted to the Directorate for Pharmaceutical Affairs (DPA) by a medical consultant.

• In case of an application for a drug/indication which has never been approved in the past, counter endorsement by the respective clinical chair is also required.
• EMT which has previously been approved through the EMTC for the same requested indication, also require counter endorsement by the respective clinical chair, however the clinical chair can delegate authority to endorse requests to respective lead clinicians.
• No counter-endorsement is required for renewal or change in dose of previously approved treatment.
• A critical request is defined as a submission for medicinal treatment which, if not administered immediately, can result in life-threatening consequences for the patient and thus needs to be initiated with immediate effect. In this scenario, the medical doctor can endorse the request on behalf of the clinical chair/lead clinician/consultant in order for an emergency supply to be provided until the next working day of the respective department, after which the normal submission procedures are to be carried out.

You can easily reach the department by visiting the “Contact Us” section on our website.